PwPepwise

FGL

Brain & Focus

NCAM-mimetic peptide

FGL is a synthetic peptide derived from the second fibronectin type III module of the neural cell adhesion molecule (NCAM).

§Dosing at a glance

1 protocol · from the research
What it's forDoseHow oftenHowFor how long
General protocol25 mg—IntranasalSprayed into the nose.—

Approximate values pulled from the research — double-check before dosing.

§01Summary

FGL is a synthetic peptide derived from the second fibronectin type III module of the neural cell adhesion molecule (NCAM). It mimics NCAM's ability to activate fibroblast growth factor receptors (FGFRs), triggering signaling pathways involved in neuronal growth, survival, and synaptic plasticity. In preclinical models, FGL has been reported to enhance memory and learning, protect neurons from injury and age-related decline, and reduce neuroinflammation in the aging brain4,8,9,10,11,15.

In animal studies, FGL appears to promote synapse formation and strengthen synaptic connections in the hippocampus — the brain region central to learning and memory9,10. It has also been reported to reduce hallmarks of Alzheimer's-like pathology, including amyloid deposits and tau protein abnormalities, and to protect neurons from ischemic (stroke-related) damage8,14. A first-in-human Phase I study found intranasal administration of FGL to be well tolerated in healthy volunteers, with dose-dependent systemic exposure detected at higher doses19. Human trials exploring its therapeutic potential in neurodegenerative conditions are an active area of clinical development. It is important to note that several studies in this dataset use 'FGL' as an abbreviation for unrelated terms — including fasting glucose levels and fingolimod — and those findings do not pertain to this peptide5,6,18,20.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

FGL is a 15-amino acid synthetic peptide derived from the second fibronectin type III (FN2) module of the neural cell adhesion molecule (NCAM). It functions as a functional mimetic of NCAM's heterophilic signaling capacity by directly binding and activating fibroblast growth factor receptor 1 (FGFR1), bypassing the need for homophilic NCAM-NCAM interactions10. This receptor activation initiates downstream signaling through the MAPK (ERK1/2) and PI3K-Akt pathways, both of which are required for FGL's neurotrophic and neuroprotective effects including neurite outgrowth and neuronal survival across dopaminergic, hippocampal, and cerebellar granule neuronal populations10.

At the synaptic level, FGL facilitates the delivery of AMPA receptors to synaptic membranes through a sequential kinase cascade: initial PKC activation followed by persistent CaMKII activation4. This mechanism enhances excitatory synaptic transmission and potentiates NMDA receptor-dependent long-term potentiation (LTP) in hippocampal CA1 neurons, providing a direct mechanistic link between FGFR1 agonism and improved hippocampal-dependent cognitive performance4. FGL also promotes synaptogenesis and presynaptic functional enhancement in primary hippocampal neuron cultures, consistent with its memory-consolidating effects observed in behavioral paradigms9.

FGL exerts anti-inflammatory effects in the aging brain through a distinct signaling axis: FGFR1 activation stimulates IL-4 release from glial cells, which in turn drives ERK-dependent upregulation of neuronal CD200 — a surface glycoprotein that maintains microglial quiescence11. This mechanism helps restore the homeostatic balance of glial-synaptic interactions in aged tissue, reducing pro-inflammatory IL-1β expression and preserving synaptic protein markers such as synaptophysin11,15. In Alzheimer's model systems, FGL inhibits GSK3β through increased phosphorylation at Ser9, providing a mechanistic pathway linking FGFR1 activation to suppression of tau hyperphosphorylation and amyloid-associated neurodegeneration8.

Pharmacologically, FGL crosses the blood-brain barrier and is active via multiple administration routes including intranasal, subcutaneous, and intracisternal delivery in animal models8. In humans, intranasal administration produced dose-dependent systemic absorption, with quantifiable plasma concentrations at 100 mg (Cmax ~0.52 ng/mL) and 200 mg (Cmax ~1.38 ng/mL); CNS delivery via the olfactory route may be independent of these low systemic plasma levels19. The peptide's short plasma half-life (detectable up to 4 hours at 200 mg intranasally) suggests rapid systemic clearance, though the duration of downstream receptor-mediated effects may substantially outlast plasma exposure19.

§04Evidence & efficacy

Evidence base
317Studies
73Human
65Animal

In replicated preclinical studies, FGL promotes neurite outgrowth and neuronal survival across multiple neuronal subtypes — including dopaminergic, hippocampal, and cerebellar granule neurons — via FGFR and downstream MAPK and PI3K-Akt signaling10. FGL appears to enhance synaptic plasticity and memory consolidation in rodent models of learning, with effects demonstrated in both fear conditioning and Morris water maze paradigms9. It has been reported to facilitate synaptic delivery of AMPA receptors and potentiate long-term potentiation (LTP) in hippocampal CA1 neurons through sequential PKC and CaMKII activation4.

In Alzheimer's-relevant animal models, FGL appears to reduce amyloid immunoreactivity, tau hyperphosphorylation, microglial activation, astrocytosis, neuronal cell death, and brain atrophy induced by Aβ25-35 administration, while also preserving short-term memory8. FGL-modified nanoparticles have been reported to achieve 4.8-fold enhanced brain accumulation and to reduce Aβ deposition and tau hyperphosphorylation in 3xTg-AD mice when used as a targeting vehicle for combinatorial mitochondrial therapy12. In aged rats, FGL appears to attenuate neuroinflammation by stimulating neuronal CD200 expression via an IL-4-ERK pathway, reducing microglial activation and preserving LTP11,15. FGL has also been reported to protect hippocampal neurons from ischemic damage both in vitro and in vivo14, and to reverse depression-like behaviors and restore neurogenesis in NCAM-deficient mice13.

The sole published human study involving FGL as a peptide therapeutic was a Phase I pharmacokinetics trial with no efficacy endpoints19.

§05Safety

The available human safety data for FGL as a peptide therapeutic comes from a single Phase I study in 24 healthy male volunteers receiving single intranasal doses of 25 mg, 100 mg, or 200 mg19. All three doses were well tolerated, with no clinically notable abnormalities observed in ECG readings, vital signs, or laboratory parameters19. Only 3 of 24 subjects (13%) reported any adverse events: two subjects at the 200 mg dose experienced transient nasal burning lasting less than 3 minutes, and one subject at 25 mg reported transient runny eyes lasting less than 2 minutes19. One subject reported dizziness, vomiting, and headache more than 2 days after dosing, which the investigators did not attribute to the study drug19. No serious adverse events were reported across any dose level19.

In preclinical studies, FGL demonstrated a favorable tolerability profile. In NCAM-deficient mouse models, FGL had no behavioral effect on wild-type animals, suggesting selectivity and an absence of overt toxicity in neurologically intact subjects13. No adverse events were reported in aged rat studies involving repeated systemic administration11,15.

§06History

FGL was first identified and characterized in the early 2000s as part of a systematic effort to develop small synthetic peptides capable of mimicking the functional signaling of NCAM — a multifunctional cell adhesion molecule critical for neural development, synaptic plasticity, and neuronal survival. The peptide was derived from the second fibronectin type III module of NCAM and was identified as a functional agonist of FGFR1, offering a pharmacologically tractable surrogate for the complex NCAM protein itself.

The foundational mechanistic work was published in 2004, establishing that FGL activates FGFR1 to promote neurite outgrowth and neuronal survival via MAPK and PI3K-Akt signaling across multiple neuronal subtypes10, and simultaneously demonstrating its ability to enhance memory consolidation and presynaptic function in rodent behavioral models9. These landmark studies, which have each accumulated over 150 citations, established FGL as a scientifically credible lead compound for cognitive and neuroprotective indications.

Subsequent preclinical work through the late 2000s and early 2010s expanded the mechanistic profile, demonstrating anti-inflammatory effects via CD200-IL-4-ERK signaling in aged rats11, neuroprotection in ischemia models14, reversal of depression-like phenotypes in NCAM-deficient mice13, and attenuation of Alzheimer's-like pathology8. The molecular basis for synaptic cognitive enhancement through AMPA receptor trafficking was further delineated in 20124.

The first human study — a Phase I tolerability and pharmacokinetics trial of the intranasal formulation in healthy volunteers — was published in 2007, confirming acceptable tolerability and dose-dependent systemic exposure19. More recently, FGL has been explored as an active targeting ligand for brain-directed nanoparticle drug delivery systems in Alzheimer's disease models12, reflecting continued interest in leveraging its FGFR1-binding properties for CNS therapeutic applications.

§07References